MBody AI Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 3.4
- Dividend yield
- –
About MBody AI
Services-Computer Integrated Systems Design, SIC 7373
Check-Cap Ltd. is a clinical-stage medical diagnostics company focused on developing screening technologies for the gastrointestinal tract. Its primary product candidate is C-Scan, an ingestible capsule system comprising the C-Scan Cap, C-Scan Track, and C-Scan View. The system uses imaging alongside an oral contrast agent to detect colorectal abnormalities. Check-Cap designs its diagnostic solutions for patients requiring gastrointestinal screening, alongside physicians and clinical healthcare providers.
The enterprise operates from principal executive offices, research and development facilities, and manufacturing sites located in Isfiya, Mount Carmel, Israel. Geographically, Check-Cap focuses its clinical development and commercial distribution across Israel, the United States, Europe, and Japan. In addition to its core operations, the company holds franchise rights in New Jersey. Check-Cap relies on centralized facilities and third-party relationships to support its clinical and operational footprint.
Summary of the business section of MBody AI's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MBody AI Ltd.
- Headquarters
- Isfiya, Israel
- Address
- Abba Hushi Avenue, P.O. Box 1271 000000
- Phone
- 972-4-8303400
- Website
- mbody.ai
- Employees
- 8,289, Dec 31, 2024
- Industry
- Services-Computer Integrated Systems Design
- Incorporated in
- L3
- Auditor
- BCRG Group, Irvine, CA
Stock & identifiers
- Ticker
- MBAI
- Exchange
- Nasdaq
- IPO date
- Feb 20, 2015
- Shares outstanding
- 7M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-7 reverse, Aug 13, 2026; 1-for-19.67 reverse, Mar 31, 2023; 1-for-20 reverse, Nov 25, 2022; 1-for-12 reverse, Apr 4, 2018; 1-for-12 reverse, Apr 4, 2018
- SEC CIK
- 1610590
- CUSIP
- M6S83C106
- ISIN
- USM6S83C1065
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Alexander Fowler | Chief Executive Officer, Director | 670,064 |
| Timothy John Hayden | Chief Financial Officer | 79,717 |
| Alan D. Lewis | CFO | – |
| Kai Michael Toft Sorensen | Director | 4,028 |
| Masri Ghaleb El | Director | – |
| Scott Robertson Walters | Director | 79,717 |
| Regan McMillan McGee | Director | 6,860,097 |
| Anurag Dilip Sharma | Director | – |
| David Lontini | Director | – |
| Carlos Cheung | Director | – |
| Daniel Kokiw | Director | – |
| Michael Hutton | Director | – |
Employees
Headcount reported in annual reports
“The CRC-PREVENT trial included 8,289 individuals with diverse racial, ethnic, and socioeconomic backgrounds across more than 2,900 zip codes in all lower 48 states, with colonoscopies performed in more than 3,800 endoscopy centers.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 28, 2026 | Name change | Name changed from Check-Cap Ltd to MBody AI Ltd. |
| May 1, 2025 | Late filing | Notification of late filing |
| May 1, 2024 | Late filing | Notification of late filing |
| May 1, 2023 | Delisting | Notice of delisting from exchange (Form 25) |
| Feb 20, 2020 | Delisting | Notice of delisting from exchange (Form 25) |
| May 3, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
| Feb 20, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 11, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |